We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

94 hedge funds and large institutions have $573M invested in LENZ Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

29% more capital invested

Capital invested by funds: $445M → $573M (+$128M)

21% more funds holding

Funds holding: 78 → 94 (+16)

4.1% more ownership

Funds ownership: 68.13% → 72.23% (+4.1%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
94
Holders Change
+16
Holders Change %
+20.51%
% of All Funds
1.24%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
33
Reduced
20
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$23.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.4M
3
BlackRock
BlackRock
New York
+$6.88M
4
State Street
State Street
Massachusetts
+$6.25M
5
UBS Group
UBS Group
Switzerland
+$2.43M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$8.23M
2
SB
Samsara BioCapital
California
-$6.75M
3
PHP
Parkman Healthcare Partners
Connecticut
-$3.31M
4
SSA
Schonfeld Strategic Advisors
New York
-$2.55M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$1.39M -$514K -16,853 -26%
VCM
27
Vivaldi Capital Management
Illinois
$1.39M -$76.2K -2,500 -4%
HCA
28
Harbor Capital Advisors
Illinois
$1.27M +$1.34M +43,989 New
BP
29
BBR Partners
New York
$1.15M – – –
BFM
30
Boothbay Fund Management
New York
$1.15M -$446K -14,633 -27%
Bank of America
31
Bank of America
North Carolina
$1.1M +$561K +18,395 +93%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$983K -$4.69K -154 -0.5%
American Century Companies
33
American Century Companies
Missouri
$938K +$263K +8,631 +36%
Barclays
34
Barclays
United Kingdom
$868K +$414K +13,594 +83%
RSCM
35
Rock Springs Capital Management
Maryland
$846K +$893K +29,305 New
Bank of New York Mellon
36
Bank of New York Mellon
New York
$843K -$13K -428 -1%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$815K +$110K +3,595 +15%
KPWS
38
Kestra Private Wealth Services
Texas
$788K -$6.1K -200 -0.7%
Renaissance Technologies
39
Renaissance Technologies
New York
$732K -$729K -23,900 -49%
N
40
Nuveen
North Carolina
$668K – – –
DIM
41
Delta Investment Management
California
$555K +$587K +19,241 New
Swiss National Bank
42
Swiss National Bank
Switzerland
$546K +$576K +18,900 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$541K +$33.5K +1,100 +6%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$511K +$540K +17,716 New
Citigroup
45
Citigroup
New York
$504K +$253K +8,306 +91%
Two Sigma Investments
46
Two Sigma Investments
New York
$493K -$257K -8,428 -33%
KFA
47
Kelleher Financial Advisors
New York
$491K -$114K -3,750 -18%
RI
48
Rinkey Investments
California
$438K – – –
Deutsche Bank
49
Deutsche Bank
Germany
$281K +$133K +4,370 +82%
BCM
50
BML Capital Management
Indiana
$268K -$1.55M -50,729 -85%
1
2
3 4 5

LENZ Hedge Fund Activity: Q4 2024 in Review

94 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2024, worth a combined $573M — up 29% from $445M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LENZ positions and 8 closed out — a net gain of 16 holders — while 33 added to existing stakes and 20 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $23.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.23M sold.

  • 94 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2024, up from 78 in Q3 2024.
  • Funds reported $573M of LENZ Therapeutics stock for Q4 2024, up 29% quarter-over-quarter.
  • 24 funds opened new LENZ Therapeutics positions in Q4 2024 and 8 closed out, a net change of +16 holders.
  • The largest LENZ Therapeutics buyer in Q4 2024 was Paradigm Biocapital Advisors, an estimated $23.5M added.
  • The largest LENZ Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $8.23M sold.

Based on aggregated 13F filings for Q4 2024.